Global Traveler's Diarrhea Market is segmented By Drug Class (Antibiotics, Oral Rehydration Therapy (ORS), Antidiarrheal Agents, Vaccines/Prophylactics, Others), By Pathogen (Bacteria, Viruses, Protozoa), By Age Group (Adults, Children), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Traveler's Diarrhea Market Size
The global traveler's diarrhea market size was valued US$ YY billion in 2022 and is estimated to reach US$ YY billion by 2031, growing at a high CAGR during the forecast period (2024-2031).
Traveler's diarrhea is a digestive tract disorder characterized by an intestinal infection that occurs when a person consumes contaminated food and water.
Traveler's Diarrhea Market Scope
|
Metrics |
Details |
|
CAGR |
High |
|
Size Available for Years |
2022-2031 |
|
Forecast Period |
2024-2031 |
|
Data Availability |
Value (US$) |
|
Segments Covered |
By Drug Class, By Pathogen, By Age Group, By Distribution Channel and Region |
|
Regions Covered |
North America, Europe, Asia-Pacific, South America and Middle East & Africa |
|
Fastest Growing Region |
Asia-Pacific |
|
Largest Region |
North America |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For More Insights Request free Sample
Traveler's Diarrhea Market Dynamics
The traveler's diarrhea market growth is driven due to the surge in the number of travelers, rising awareness among travelers, development of novel treatments is anticipated to drive the traveler’s diarrhea market.
Surge in the number of travelers, is expected to drive the global traveler’s diarrhea market growth
The risk of acquiring traveler’s diarrhea is high in developing countries like Africa, the Middle East, Asia, and Latin America. An increase in the number of travelers to developing countries in these regions is driving the number of traveler’s diarrhea patients. For instance, according to The World Tourism Organization (UNWTO), in 2018, estimated international tourist arrivals (overnight visitors) increased 6% to 1.4 billion across the world. According to the world atlas, Southeast Asia receives the highest number of travelers, and an estimated 55.6 million people visited China, Thailand received 24.8 million visitors, South Korea welcomed 14.2 million, Japan 13.4 million, and Indonesia received 10.4 million visitors annually. As per the Center for Disease Control and Prevention (CDC), in 2016, more than 6 million international travelers visited Brazil. The rise in the number of travelers is boosting travel expenditure. For instance, according to The U.S. Travel Association, in the U.S., an estimated US$ 1.1 trillion was spent by domestic and international inbound travelers.
Growing awareness among travelers, is expected to drive the global traveler’s diarrhea market growth
The rise in awareness among travelers is anticipated to drive the global traveler’s diarrhea market. For instance, pre-travel counseling is essential due to a rise in the number of travelers and knowledge related to traveler’s medicine. The goal of pre-travel consultation is to improve the understanding of travelers about travel-related health hazards and diseases.
Growing self-medication by using OTC products coupled with antibiotic resistance is likely to hamper the market growth
An increase in the use of over-the-counter medication to treat traveler’s diarrhea is anticipated to hamper the market. For instance, according to an article published in The Journal of Life and Environmental Sciences, the study conducted during 2013-2014 in China Mainland, the estimated rate of antibiotic misuse was 35.12%.
The rise in the use of antibiotics increases the risk of antibiotic resistance. Therefore, as per WHO guidelines, antibiotics are restricted to cholera with severe dehydration and bloody diarrhea.
COVID-19 Impact Analysis
Following the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries globally, and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the coronavirus (COVID-19) manifestation has resulted in more than 52.7 million infected individuals worldwide as of November 13, 2020.
COVID-19 has affected every market globally and has also impacted the global traveler’s diarrhea market in the following ways; by directly affecting production and demand, creating disruptions in distribution channels, and its financial impact on firms and financial markets.
Furthermore, players operating in the global traveler’s diarrhea market face significant challenges on various fronts due to the COVID-19 pandemic. The significant challenges include the supply of raw materials for manufacturing drug formulations due to irregularities in the transportation facility. Moreover, distributors of products are experiencing irregular demand for products from the retailers due to the increasing patient population suffering from COVID-19 and other life-threatening disorders.
Traveler's Diarrhea Market Segmentation Analysis
The antibiotics segment is expected to hold largest share in this market segment
Antibiotics used to treat and manage traveler’s diarrhea have evolved rapidly in the past 50 years due to various factors, including drug resistance, costs, and side effects. However, with consistent developments in research, new and improved treatments for traveler’s diarrhea are entering the traveler’s diarrhea market.
The Food and Drug Administration (FDA) has approved several new treatments and drugs in recent years. For instance, Aemcolo, an oral antibacterial rifamycin, was approved by the FDA in November 2018 to treat traveler’s diarrhea caused by E. coli. Clinical studies have revealed that rifamycin has greater efficiency in reducing diarrhea symptoms than placebo. Antibiotics are primarily recommended to treat severe traveler’s diarrhea. Despite a few side effects, antibiotics are likely to stay ahead within the drug class segment. The management and treatment of traveler’s diarrhea are expected to evolve, owing to the formulation of different guidelines laid down by regulatory bodies worldwide. As per the new guidelines, antibiotics for mild traveler’s diarrhea are not recommended, as they have been linked to adverse events.
The bacteria segment is expected to hold largest share in this market segment
According to CDC Center for Disease Control and Prevention, bacteria cause nearly 80% of the cases. E. coli and Salmonella Spp are the two major bacteria types responsible for traveler’s diarrhea. According to the British Medical Journal, the prevalence of traveler’s diarrhea is higher among travelers visiting regions in South Asia and Southeast Asia.
The adults traveler’s diarrhea segment is expected to hold largest share in this market segment
According to the American family physician journal, Traveler’s diarrhea is more common in young children than in adults, and they have a higher risk of dehydration and severe illness. The use of oral rehydration solutions is essential, and parents should include prepackaged packets (to be mixed with safe water) in their travel kits.
The retail pharmacies segment is expected to hold largest share in this market segment
A retail pharmacy refers to an independent pharmacy with a state license to dispense medications to the general public. People are increasingly adopting retail pharmacies as a one-stop shop to buy medicines. They are highly preferred by people who cannot reach hospitals for a check-up regularly and need medicine for quick treatment. The better outreach of retail pharmacies makes them a highly profitable segment and the most established one across several countries.
Traveler's Diarrhea Market Geographical Share
North America region holds the largest market share of global traveler’s diarrhea market
The North American region holds the largest share of the market due to the increasing burden of traveler’s diarrhea and the strong presence of manufacturers in this region. The rising awareness, along with the easy availability of over-the-counter medications, is likely to favor the growth of the traveler’s diarrhea market in North America. For instance, according to The U.S. Travel Association, in the U.S., an estimated US$ 1.1 trillion was spent by domestic and international inbound travelers. In April 2019, Health Canada approved Travelan in Canada.
Traveler's Diarrhea Market Competitive Landscape
The global traveler's diarrhea market is highly competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include Bausch Health Companies Inc. (Salix Pharmaceuticals), Bristol-Myers Squibb Company, Cosmo Pharmaceuticals NV, Immuron Limited, Johnson & Johnson, Pfizer Inc., Procter & Gamble, Sanofi SA, Valneva Canada Inc, Sun Pharmaceutical Industries Ltd. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, In November 2018, COSMO PHARMACEUTICALS received U.S. Food and Drug Administration approval for Aemcolo for the treatment of traveler’s diarrhea.
Key Companies to Watch
Bausch Health Companies Inc
Company Overview: Bausch Health Companies Inc. is a multinational specialty pharmaceutical company based in Laval, Quebec, Canada. Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies committed to the prevention and treatment of gastrointestinal (GI) diseases and disorders. It manufactures and markets a broad range of branded and generic pharmaceuticals, over-the-counter (OTC) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetic devices) directly or indirectly in more than 90 countries and regions, including the United States, Canada, Europe, the Middle East, Africa, Asia Pacific and Latin America. Each day, its products are used by up to 150 million people around the world.
Product portfolio: The Company’s portfolio comprised of include have a diversified portfolio of products, with a core focus in the following areas Eye health (Bausch + Lomb), Gastrointestinal Diseases (Salix Pharmaceuticals), Dermatology (Ortho Dermatologics).
Key Developments: In October 2019, Bausch Health Companies Inc. announced the receipt of the U.S. patent and Trademark patent covering use of XIFAXAN. This enabled the company to strengthen the intellectual property of XIFAXAN.
Why Purchase the Report?
- Visualize the composition of the traveler's diarrhea market segmentation by drug class, pathogen, age group, distribution channel and region highlighting the key commercial assets and players.
- Identify commercial opportunities in traveler's diarrhea market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of traveler's diarrhea market - level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
The global traveler's diarrhea market report would provide an access to an approx. 69 market data table, 63 figures and 200 pages.
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
